Lokelma approved in China for the treatment of adult patients with hyperkalaemia

6 January 2020 - Patients in China will benefit from Lokelma’s rapid reduction of potassium in the blood and the ...

Read more →

China National Medical Products Administration approves BeiGene’s tislelizumab for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies

27 December 2019 - Second BeiGene discovered drug to receive regulatory approval, first in China. ...

Read more →

AstraZeneca’s triple-combination therapy approved in China for patients with COPD

23 December 2019 - First fixed-dose triple-combination therapy in a pressurised metered-dose inhaler device in China. ...

Read more →

China’s cancer patients hit by new law on experimental drug treatments not approved by government

11 December 2019 - The law came into effect on December 1 and forbids pharmaceutical firms giving patients drugs from unapproved ...

Read more →

China to strengthen medicine price monitoring

9 December 2019 - China's National Healthcare Security Administration has issued a guideline to strengthen regular supervision on medicine prices. ...

Read more →

How China’s new drug buying program is causing pain

6 December 2019 - China is overhauling its health-care system with the aim of providing broader access to quality drugs for ...

Read more →

China updates drug reimbursement list, agrees price cuts

2 December 2019 - Drugs added include AbbVie's Humira and Roche's Perjeta. ...

Read more →

National Medical Products Administration approves Chipscreen Bioscience's chidamide (Epidaza) for breast cancer indication

29 November 2019 - Shenzhen Chipscreen Biosciences announced that the company's lead innovative product Epidaza (chidamide), an oral subtype-selective histone ...

Read more →

Sosei Heptares announces that the COPD treatment Ultibro Breezhaler has been included in the National Reimbursement Drug List in China

28 November 2019 - Sosei Group announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included ...

Read more →

Tyvyt (sintilimab Injection), an innovative PD-1 inhibitor jointly developed by Innovent and Lilly, is included in the new catalogue of National Reimbursement Drug List

27 November 2019 - Innovent Biologics today jointly announced with Eli Lilly and Company that the innovative PD-1 inhibitor Tyvyt (sintilimab ...

Read more →

Chi-Med’s Elunate (fruquintinib capsules) included in the National Reimbursement Drug List in China

28 November 2019 - Hutchison China MediTech today announces that Elunate (fruquintinib capsules), its national class 1 targeted anticancer drug for ...

Read more →

Drug makers including Roche and Novartis slash medicine prices in China to get on reimbursement list

28 November 2019 - Drug makers including Roche and Novartis have agreed to cut the prices of some of their ...

Read more →

Astellas announces the approval of Xtandi (enzalutamide) by the China National Medical Products Administration approval based on Asian PREVAIL study of men with metastatic castration-resistant prostate cancer

26 November 2019 - Astellas Pharma today announced that the China National Medical Products Administration approved a new drug application ...

Read more →

Merck’s Keytruda (pembrolizumab) now approved in China for first-line treatment of metastatic squamous non-small cell lung cancer in combination with chemotherapy

26 November 2019 - Third approval for Keytruda in first-line NSCLC in China in less than one year. ...

Read more →

China to promote centralised medicine procurement, use to ease patients' burden

20 November 2019 - China will improve its mechanism for centralized medicine procurement and use in a steady and orderly ...

Read more →